• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

Checkpoint Therapeutics

Checkpoint Therapeutics
January 26, 2022
Pharmaceutical News

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab

Waltham, Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:  CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced  positive topline results from its registration-enabling clinical trial evaluating the safety and  efficacy of its anti-PD-L1 antibody, cosibelimab, administered as a fixed dose of 800 mg every  two

More
Checkpoint Therapeutics
Pharmaceutical News

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab

January 26, 2022

Waltham, Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:  CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced  positive topline results from

More
  • Can You Sue Your Doctor for Blindness Caused by Elmiron®?
  • Experts advise European SME packaging firms to expand or seek acquisition prior to Pharmapack Europe
  • FIP advances sustainable health systems by providing new guidance for self-managing reflux symptoms
  • APAC overview: trends, challenges, and possibilities for growth in the MarTech sector
  • Modernizing Therapeutic Cell Production

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop